Genetic Immunity's DermaVir Patch is our candidate Therapeutic Vaccine designed for HIV-specific
immune reconstitution. The Antiviral Mechanism of Action is based on inhibition of viral
replication by cytotoxic killing of HIV-infected cells. Currently, there are no approved immune therapy or vaccine products
on the market for HIV/AIDS.
Clinical Trials involving DermaVir Patch, 2009:
|
Location (clinicaltrials.gov ID) |
Title | Status |
|
GIHU004 Hungary (NCT00712530) To read Study Synopsis click here... |
A Phase I Study to Evaluate the Tolerability and Safety of DermaVir Immune Therapy in HIV-infected Subject under Treatment with HAART | Excellent safety, tolerability, and immunogenicity: DermaVir evoked long-lasting gag-specific T cells 6- to 18,000 fold above pre-treatment values in all nine patients, in dose dependent manner. |
|
ACTG 5176 USA (NCT00270205) To read Study Synopsis click here... |
A Phase I/II, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability and Immunogenicity of DermaVir Patch Immune Therapy in HIV-infected Subjects Currently Under Treatment with HAART | 24 of the 24 patients enrolled, the trial is still blinded. |
|
GIEU006 Germany (NCT00711230) To read Study Synopsis click here... |
A Phase II, Randomized, Study to Evaluate the Safety, Tolerability, Immunogenicity and Antiviral Activity of DermaVir Patch Immune Therapy in HIV-1 Infected treatment-naïve Subjects | 36 of the 36 patients are enrolled. Trial so far shows excellent safety and tolerability, still blinded for efficacy. |
|
PHPC-02 Italy To read Study Synopsis click here... |
Antiretroviral sparing concept: a Phase II, randomized, single blind placebo controlled study to investigate the effect of DermaVir immunization on the quantity of HIV-specific T cells during HAART followed by analytical treatment interruption | 16 of the 16 patients enrolled, the trial is still blinded. |
|
IMPAACT-P1049 USA |
A Phase I/II study of the safety, tolerability and immunogenecity of a topical therapeutic DNA denritic cell vaccine (DermaVir Patch) in children, adolescents and young adults with hiv-1 infection on highly active antiretroviral therapy (HAART). | In preparation |